CriticalFirst-generation antipsychotic, aliphatic-side-chain phenothiazine×Class III antiarrhythmic
Updated · Methodology
Mechanism
Dronedarone can moderately prolong the Bazett heart-rate-corrected QT interval (QTc), by about 10 ms (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). The US label estimates a 15 ms increase at 400 mg twice daily with food (dronedarone label, US Food and Drug Administration, FDA). Chlorpromazine is a phenothiazine neuroleptic. Phenothiazine neuroleptics can increase QT prolongation, which raises the risk of severe torsade de pointes ventricular arrhythmia that can end in sudden death (chlorpromazine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For this reason, both dronedarone documents contraindicate dronedarone with drugs that can induce torsade de pointes and name phenothiazines first among the examples (EMA, FDA). The documents describe no pharmacokinetic interaction. CYP3A4 is the main enzyme that metabolises dronedarone. CYP1A2 inhibitors raise chlorpromazine levels, and dronedarone does not significantly inhibit CYP1A2 (dronedarone SmPC, EMA; chlorpromazine SmPC, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). With chlorpromazine, QT prolongation that can trigger ventricular arrhythmia is a common adverse reaction. Ventricular arrhythmia, ventricular fibrillation and tachycardia, torsade de pointes, cardiac arrest and sudden death occur with unknown frequency. QT prolongation is worse with a slow heart rate, low potassium and congenital or acquired (for example drug-induced) long QT (chlorpromazine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label reports nonspecific, usually reversible Q and T wave distortions on the ECG in some patients. Sudden death, apparently due to cardiac arrest, has also been reported (chlorpromazine label, US Food and Drug Administration, FDA). Adverse reactions of dronedarone include a slow heart rate and prolongation of the heart-rate-corrected QT interval. A proarrhythmic effect is possible with drugs that promote arrhythmias and with electrolyte disorders (dronedarone SmPC, European Medicines Agency, EMA).
Management
The combination is contraindicated. Both dronedarone documents contraindicate dronedarone with drugs that can induce torsade de pointes and name phenothiazines explicitly (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA; dronedarone label, US Food and Drug Administration, FDA). Chlorpromazine is a phenothiazine neuroleptic (chlorpromazine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish chlorpromazine SmPC, for its part, does not recommend combining chlorpromazine with other QT-prolonging drugs, including some antiarrhythmics (AEMPS). Dronedarone prolongs QT according to its own documents (EMA, FDA). Dronedarone is also contraindicated with a heart rate below 50 beats per minute and with a Bazett heart-rate-corrected QT interval (QTc) of 500 ms or more. If any of its contraindications develops during treatment, dronedarone is stopped (EMA). Where possible, make sure before starting chlorpromazine that there are no factors that favour ventricular arrhythmia. These are a heart rate below 55 beats per minute, low potassium, congenital long QT and current treatment with drugs that can cause marked bradycardia, low potassium, depressed intracardiac conduction or QT prolongation. Except in emergencies, the initial assessment includes an electrocardiogram (ECG) (AEMPS). Potassium or magnesium deficiency is corrected before dronedarone is started and during treatment. Monitoring, including an ECG, is recommended during treatment, and dronedarone is stopped if the QTc is 500 ms or more (EMA). No document sets an interval between stopping one drug and starting the other. Dronedarone and its metabolite are fully cleared from plasma 2 weeks after stopping, and the half-life of chlorpromazine is variable, about 30 hours (dronedarone SmPC, EMA; chlorpromazine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Clorpromazina (nº registro 42934), sección 4.4 (2023)– AEMPS, CIMA, nº registro 42934 (Largactil 100 mg comprimidos recubiertos con película, Neuraxpharm Spain), revisión 07/2023, secciones 4.3, 4.4, 4.5, 4.8 y 5.2
- FDA: Chlorpromazine Hydrochloride Tablets, USP (chlorpromazine) prescribing information (2026)– FDA, DailyMed setid aa086a21-de85-4b03-af58-49b70acf8cf0 (Amneal Pharmaceuticals NY), versión 9 (05/2026), texto Rev. 12-2019, Contraindications, Precautions y Adverse Reactions